Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Get in touch

1800 437 222

Viral hepatitis (A, B & C)

Hepatitis means inflammation of the liver, and it can be caused by a virus or other non-viral causes.  The main difference between the viruses is how they are spread and the effects they have on your health.

Read more...

Prevention

There are safe and effective vaccines that protect you from getting hepatitis A and B.  While there is no vaccine for hep C, by being ‘blood aware’ you can reduce your overall chance of being exposed to the virus.

Read more...

Living with Hepatitis

People with chronic hepatitis can do a number of things to stay healthy including limiting/avoiding alcohol, reducing stress, not smoking, getting regular exercise and eating a healthy diet.

Read more...

Treatment

Effective treatment is available for both chronic hepatitis B and C.  Before you can see a liver specialist to talk about going on treatment, you need to get a referral from your GP first.

Read more...
ContentViewArticle Object
(
    [item:protected] => stdClass Object
        (
            [id] => 307
            [asset_id] => 381
            [title] => PBAC Submissions - you can influence change 
            [alias] => pbac-submissions-you-can-influence-change
            [title_alias] => 
            [introtext] => You have an opportunity to have your say and influence change in hepatitis C treatments in Australia.

Some medications have been recommended for listing on PBS - and now we have even more possible treatments. What is coming next?

The Pharmaceutical Benefits Advisory Committee (PBAC) is meeting in July 2015, and again there are new and exciting hepatitis C treatments on the agenda. The PBAC is the group that makes recommendations to the Government on medications to be made available to all Australians through the Pharmaceutical Benefit Scheme (PBS). The PBS makes medications affordable and accessible for all Australians.

The new hepatitis C medication on the agenda is:
  • Viekira Pak® - paritaprevir with ritonavir, ombitasvir and dasaburvir
  • Viekira Pak-RBV® - paritaprevir with ritonavir, ombitasvir, dasaburvir and ribavirin (Please note these first two, multi-agent medicines are listed on the PBAC agenda as a single entry.)
The existing medicines that are being considered for additional uses are:
  • Simeprevir (Olysio ®) – for use in an interferon-free combination
  • Ribavirin (Ibavyr®) – as per submission to the March 2015 meeting with revisions.
Hepatitis Queensland is preparing a submission to the PBAC in support of these treatments and we encourage people whose lives are affected by viral hepatitis to also make a submission.

The process for making a submission is simple and is exactly the same as it was for the March meeting. The PBAC submissions are due by close of business on 10 June 2015. Get the facts about why Australians need access to these new medications and information about the process of making a submission.

Have your voice heard and complete a submission. When you make your submission you have the option to make a submission on one of these four medications listed above, or on combinations of medications, or you can make a submission on ‘all hepatitis C treatments’.

Some of the factors to consider when making your submission:
    There are almost a quarter-of-a-million Australians living with chronic hepatitis C
  • With high prevalence and sub-optimal access to treatment, the burden of disease from hepatitis C is set to rise significantly
  • The current treatments offered under the PBS in Australia are less effective, require longer dosing periods and have more side-effects than the new generation of treatments being considered
  • The new treatments offer a greater chance for people to be cured and be free of hepatitis C
  • If Australia responds in a timely and effective way, these medications could see the virtual elimination of hepatitis C in Australia.
If you have any questions in relation to making a submission or would like to contribute directly to Hepatitis Queensland submission please contact Lana on (07) 3846 0020 or abc@hepqld.asn.au by 5 June 2015.

Older news:

[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2015-06-03 03:22:45 [created_by] => 66 [created_by_alias] => [modified] => 2015-06-03 03:24:05 [modified_by] => 66 [checked_out] => 66 [checked_out_time] => 2015-06-03 03:24:05 [publish_up] => 2015-06-03 03:22:45 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 2 [parentid] => 0 [ordering] => 87 [metakey] => [metadesc] => [access] => 1 [hits] => 1716 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 307:pbac-submissions-you-can-influence-change [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/307-pbac-submissions-you-can-influence-change [text] => You have an opportunity to have your say and influence change in hepatitis C treatments in Australia.

Some medications have been recommended for listing on PBS - and now we have even more possible treatments. What is coming next?

The Pharmaceutical Benefits Advisory Committee (PBAC) is meeting in July 2015, and again there are new and exciting hepatitis C treatments on the agenda. The PBAC is the group that makes recommendations to the Government on medications to be made available to all Australians through the Pharmaceutical Benefit Scheme (PBS). The PBS makes medications affordable and accessible for all Australians.

The new hepatitis C medication on the agenda is:
  • Viekira Pak® - paritaprevir with ritonavir, ombitasvir and dasaburvir
  • Viekira Pak-RBV® - paritaprevir with ritonavir, ombitasvir, dasaburvir and ribavirin (Please note these first two, multi-agent medicines are listed on the PBAC agenda as a single entry.)
The existing medicines that are being considered for additional uses are:
  • Simeprevir (Olysio ®) – for use in an interferon-free combination
  • Ribavirin (Ibavyr®) – as per submission to the March 2015 meeting with revisions.
Hepatitis Queensland is preparing a submission to the PBAC in support of these treatments and we encourage people whose lives are affected by viral hepatitis to also make a submission.

The process for making a submission is simple and is exactly the same as it was for the March meeting. The PBAC submissions are due by close of business on 10 June 2015. Get the facts about why Australians need access to these new medications and information about the process of making a submission.

Have your voice heard and complete a submission. When you make your submission you have the option to make a submission on one of these four medications listed above, or on combinations of medications, or you can make a submission on ‘all hepatitis C treatments’.

Some of the factors to consider when making your submission:
    There are almost a quarter-of-a-million Australians living with chronic hepatitis C
  • With high prevalence and sub-optimal access to treatment, the burden of disease from hepatitis C is set to rise significantly
  • The current treatments offered under the PBS in Australia are less effective, require longer dosing periods and have more side-effects than the new generation of treatments being considered
  • The new treatments offer a greater chance for people to be cured and be free of hepatitis C
  • If Australia responds in a timely and effective way, these medications could see the virtual elimination of hepatitis C in Australia.
If you have any questions in relation to making a submission or would like to contribute directly to Hepatitis Queensland submission please contact Lana on (07) 3846 0020 or abc@hepqld.asn.au by 5 June 2015.

Older news:

[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) [params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [print:protected] => [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 307 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [user:protected] => JUser Object ( [isRoot:protected] => [id] => 0 [name] => [username] => [email] => [password] => [password_clear] => [usertype] => [block] => [sendEmail] => 0 [registerDate] => [lastvisitDate] => [activation] => [params] => [groups] => Array ( ) [guest] => 1 [lastResetTime] => [resetCount] => [_params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( ) ) [_authGroups:protected] => Array ( [0] => 1 ) [_authLevels:protected] => Array ( [0] => 1 [1] => 1 ) [_authActions:protected] => [_errorMsg:protected] => [_errors:protected] => Array ( ) [aid] => 0 ) [_name:protected] => article [_models:protected] => Array ( [article] => ContentModelArticle Object ( [_context:protected] => com_content.article [_item:protected] => Array ( [307] => stdClass Object ( [id] => 307 [asset_id] => 381 [title] => PBAC Submissions - you can influence change [alias] => pbac-submissions-you-can-influence-change [title_alias] => [introtext] => You have an opportunity to have your say and influence change in hepatitis C treatments in Australia.

Some medications have been recommended for listing on PBS - and now we have even more possible treatments. What is coming next?

The Pharmaceutical Benefits Advisory Committee (PBAC) is meeting in July 2015, and again there are new and exciting hepatitis C treatments on the agenda. The PBAC is the group that makes recommendations to the Government on medications to be made available to all Australians through the Pharmaceutical Benefit Scheme (PBS). The PBS makes medications affordable and accessible for all Australians.

The new hepatitis C medication on the agenda is:
  • Viekira Pak® - paritaprevir with ritonavir, ombitasvir and dasaburvir
  • Viekira Pak-RBV® - paritaprevir with ritonavir, ombitasvir, dasaburvir and ribavirin (Please note these first two, multi-agent medicines are listed on the PBAC agenda as a single entry.)
The existing medicines that are being considered for additional uses are:
  • Simeprevir (Olysio ®) – for use in an interferon-free combination
  • Ribavirin (Ibavyr®) – as per submission to the March 2015 meeting with revisions.
Hepatitis Queensland is preparing a submission to the PBAC in support of these treatments and we encourage people whose lives are affected by viral hepatitis to also make a submission.

The process for making a submission is simple and is exactly the same as it was for the March meeting. The PBAC submissions are due by close of business on 10 June 2015. Get the facts about why Australians need access to these new medications and information about the process of making a submission.

Have your voice heard and complete a submission. When you make your submission you have the option to make a submission on one of these four medications listed above, or on combinations of medications, or you can make a submission on ‘all hepatitis C treatments’.

Some of the factors to consider when making your submission:
    There are almost a quarter-of-a-million Australians living with chronic hepatitis C
  • With high prevalence and sub-optimal access to treatment, the burden of disease from hepatitis C is set to rise significantly
  • The current treatments offered under the PBS in Australia are less effective, require longer dosing periods and have more side-effects than the new generation of treatments being considered
  • The new treatments offer a greater chance for people to be cured and be free of hepatitis C
  • If Australia responds in a timely and effective way, these medications could see the virtual elimination of hepatitis C in Australia.
If you have any questions in relation to making a submission or would like to contribute directly to Hepatitis Queensland submission please contact Lana on (07) 3846 0020 or abc@hepqld.asn.au by 5 June 2015.

Older news:

[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2015-06-03 03:22:45 [created_by] => 66 [created_by_alias] => [modified] => 2015-06-03 03:24:05 [modified_by] => 66 [checked_out] => 66 [checked_out_time] => 2015-06-03 03:24:05 [publish_up] => 2015-06-03 03:22:45 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 2 [parentid] => 0 [ordering] => 87 [metakey] => [metadesc] => [access] => 1 [hits] => 1716 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 307:pbac-submissions-you-can-influence-change [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/307-pbac-submissions-you-can-influence-change [text] => You have an opportunity to have your say and influence change in hepatitis C treatments in Australia.

Some medications have been recommended for listing on PBS - and now we have even more possible treatments. What is coming next?

The Pharmaceutical Benefits Advisory Committee (PBAC) is meeting in July 2015, and again there are new and exciting hepatitis C treatments on the agenda. The PBAC is the group that makes recommendations to the Government on medications to be made available to all Australians through the Pharmaceutical Benefit Scheme (PBS). The PBS makes medications affordable and accessible for all Australians.

The new hepatitis C medication on the agenda is:
  • Viekira Pak® - paritaprevir with ritonavir, ombitasvir and dasaburvir
  • Viekira Pak-RBV® - paritaprevir with ritonavir, ombitasvir, dasaburvir and ribavirin (Please note these first two, multi-agent medicines are listed on the PBAC agenda as a single entry.)
The existing medicines that are being considered for additional uses are:
  • Simeprevir (Olysio ®) – for use in an interferon-free combination
  • Ribavirin (Ibavyr®) – as per submission to the March 2015 meeting with revisions.
Hepatitis Queensland is preparing a submission to the PBAC in support of these treatments and we encourage people whose lives are affected by viral hepatitis to also make a submission.

The process for making a submission is simple and is exactly the same as it was for the March meeting. The PBAC submissions are due by close of business on 10 June 2015. Get the facts about why Australians need access to these new medications and information about the process of making a submission.

Have your voice heard and complete a submission. When you make your submission you have the option to make a submission on one of these four medications listed above, or on combinations of medications, or you can make a submission on ‘all hepatitis C treatments’.

Some of the factors to consider when making your submission:
    There are almost a quarter-of-a-million Australians living with chronic hepatitis C
  • With high prevalence and sub-optimal access to treatment, the burden of disease from hepatitis C is set to rise significantly
  • The current treatments offered under the PBS in Australia are less effective, require longer dosing periods and have more side-effects than the new generation of treatments being considered
  • The new treatments offer a greater chance for people to be cured and be free of hepatitis C
  • If Australia responds in a timely and effective way, these medications could see the virtual elimination of hepatitis C in Australia.
If you have any questions in relation to making a submission or would like to contribute directly to Hepatitis Queensland submission please contact Lana on (07) 3846 0020 or abc@hepqld.asn.au by 5 June 2015.

Older news:

[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) ) [__state_set:protected] => 1 [_db:protected] => JDatabaseMySQLi Object ( [name] => mysqli [nameQuote:protected] => ` [nullDate:protected] => 0000-00-00 00:00:00 [dbMinimum:protected] => 5.0.4 [_database:JDatabase:private] => hepqld_joomla [connection:protected] => mysqli Object ( [affected_rows] => 1 [client_info] => 5.6.21 [client_version] => 50621 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [field_count] => 0 [host_info] => Localhost via UNIX socket [info] => Rows matched: 1 Changed: 1 Warnings: 0 [insert_id] => 0 [server_info] => 5.6.21-log [server_version] => 50621 [stat] => Uptime: 1666595 Threads: 7 Questions: 489303225 Slow queries: 167641 Opens: 7085904 Flush tables: 1 Open tables: 2000 Queries per second avg: 293.594 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 3356199 [warning_count] => 0 ) [count:protected] => 0 [cursor:protected] => 1 [debug:protected] => [limit:protected] => 0 [log:protected] => Array ( ) [offset:protected] => 0 [sql:protected] => UPDATE #__content SET hits = hits + 1 WHERE id = 307 [tablePrefix:protected] => j25_ [utf:protected] => 1 [errorNum:protected] => 0 [errorMsg:protected] => [hasQuoted:protected] => [quoted:protected] => Array ( ) ) [name:protected] => article [option:protected] => com_content [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 307 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [event_clean_cache:protected] => onContentCleanCache [_errors:protected] => Array ( ) ) ) [_basePath:protected] => /home/hepqld/public_html/components/com_content [_defaultModel:protected] => article [_layout:protected] => default [_layoutExt:protected] => php [_layoutTemplate:protected] => _ [_path:protected] => Array ( [template] => Array ( [0] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/ [1] => /home/hepqld/public_html/components/com_content/views/article/tmpl/ ) [helper] => Array ( [0] => /home/hepqld/public_html/components/com_content/helpers/ ) ) [_template:protected] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/default.php [_output:protected] => [_escape:protected] => htmlspecialchars [_charset:protected] => UTF-8 [_errors:protected] => Array ( ) [baseurl] => [document] => JDocumentHTML Object ( [_links] => Array ( ) [_custom] => Array ( ) [template] => [baseurl] => [params] => [_file] => [_template:protected] => [_template_tags:protected] => Array ( ) [_caching:protected] => [title] => PBAC Submissions - you can influence change [description] => Hepatitis Queensland [link] => [base] => http://www.hepqld.asn.au/news-media-a-events/our-news/3-news-a-events/307-pbac-submissions-you-can-influence-change [language] => en-gb [direction] => ltr [_generator] => Joomla! - Open Source Content Management [_mdate] => [_tab] => [_lineEnd] => [_charset] => utf-8 [_mime] => text/html [_namespace] => [_profile] => [_scripts] => Array ( [/media/system/js/mootools-core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/caption.js] => Array ( [mime] => text/javascript [defer] => [async] => ) ) [_script] => Array ( [text/javascript] => window.addEvent('load', function() { new JCaption('img.caption'); }); ) [_styleSheets] => Array ( ) [_style] => Array ( ) [_metaTags] => Array ( [http-equiv] => Array ( [content-type] => text/html ) [standard] => Array ( [keywords] => Hepatitis Queensland [rights] => [author] => Hepatitis Admin ) ) [_engine] => [_type] => html [_errors:protected] => Array ( ) ) [pageclass_sfx] => )

PBAC Submissions - you can influence change

You have an opportunity to have your say and influence change in hepatitis C treatments in Australia.

Some medications have been recommended for listing on PBS - and now we have even more possible treatments. What is coming next?

The Pharmaceutical Benefits Advisory Committee (PBAC) is meeting in July 2015, and again there are new and exciting hepatitis C treatments on the agenda. The PBAC is the group that makes recommendations to the Government on medications to be made available to all Australians through the Pharmaceutical Benefit Scheme (PBS). The PBS makes medications affordable and accessible for all Australians.

The new hepatitis C medication on the agenda is:
  • Viekira Pak® - paritaprevir with ritonavir, ombitasvir and dasaburvir
  • Viekira Pak-RBV® - paritaprevir with ritonavir, ombitasvir, dasaburvir and ribavirin (Please note these first two, multi-agent medicines are listed on the PBAC agenda as a single entry.)
The existing medicines that are being considered for additional uses are:
  • Simeprevir (Olysio ®) – for use in an interferon-free combination
  • Ribavirin (Ibavyr®) – as per submission to the March 2015 meeting with revisions.
Hepatitis Queensland is preparing a submission to the PBAC in support of these treatments and we encourage people whose lives are affected by viral hepatitis to also make a submission.

The process for making a submission is simple and is exactly the same as it was for the March meeting. The PBAC submissions are due by close of business on 10 June 2015. Get the facts about why Australians need access to these new medications and information about the process of making a submission.

Have your voice heard and complete a submission. When you make your submission you have the option to make a submission on one of these four medications listed above, or on combinations of medications, or you can make a submission on ‘all hepatitis C treatments’.

Some of the factors to consider when making your submission:
    There are almost a quarter-of-a-million Australians living with chronic hepatitis C
  • With high prevalence and sub-optimal access to treatment, the burden of disease from hepatitis C is set to rise significantly
  • The current treatments offered under the PBS in Australia are less effective, require longer dosing periods and have more side-effects than the new generation of treatments being considered
  • The new treatments offer a greater chance for people to be cured and be free of hepatitis C
  • If Australia responds in a timely and effective way, these medications could see the virtual elimination of hepatitis C in Australia.
If you have any questions in relation to making a submission or would like to contribute directly to Hepatitis Queensland submission please contact Lana on (07) 3846 0020 or abc@hepqld.asn.au by 5 June 2015.

Older news:

© copyright 2013 | All Rights Reserved | Website design Brisbane by iFactory